ImpriMed, Inc.

ImpriMed is a leading AI-driven precision medicine biotech startup revolutionizing cancer treatment for dogs and cats. Initially launching its advanced drug response prediction technology in 2021, the company introduced a premier service called ImpriMed Personalized Prediction Profile. The profile service leverages AI to tailor treatment strategies for pets battling blood cancers.

In addition to their premier service, ImpriMed also launched specialized canine and feline lymphoma services including Flow Cytometry, PARR, and Multidrug Sensitivity Genotyping (MDR1) with quick turnaround times and competitive pricing. As an A2LA-accredited lab, we guarantee top-quality testing and results with all our services conducted on-site at our facility in California. Our solutions have influenced 250+ US veterinary hospitals and 9,000 dogs and 700 cats with lymphoma/leukemia. Please visit our booth to explore how ImpriMed can enhance patient care.